An open‐label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease
Identifieur interne : 002453 ( Main/Exploration ); précédent : 002452; suivant : 002454An open‐label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease
Auteurs : Kelly E. Lyons [États-Unis] ; Rajesh Pahwa [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-10-30.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Accidental Falls, Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Benzothiazoles (administration & dosage), Benzothiazoles (adverse effects), Benzothiazoles (therapeutic use), Cohort Studies, Dopamine Agonists (administration & dosage), Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Dopamine agonist, Dose-Response Relationship, Drug, Drug conversion, Dyskinesia, Drug-Induced (physiopathology), Female, Humans, Indoles (administration & dosage), Indoles (adverse effects), Indoles (therapeutic use), Male, Middle Aged, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Patient Satisfaction, Pramipexole, Release, Ropinirole, dopamine agonist conversion, dopamine agonists, ropinirole prolonged release.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Benzothiazoles, Dopamine Agonists, Indoles.
- chemical , adverse effects : Antiparkinson Agents, Benzothiazoles, Dopamine Agonists, Indoles.
- chemical , therapeutic use : Antiparkinson Agents, Benzothiazoles, Dopamine Agonists, Indoles.
- drug therapy : Parkinson Disease.
- physiopathology : Dyskinesia, Drug-Induced.
- Accidental Falls, Aged, Cohort Studies, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Patient Satisfaction.
Abstract
Ropinirole prolonged release (PR) is a once daily oral dopamine agonist approved for the treatment of Parkinson's disease (PD). The goal of this 4 week, open‐label study was to determine the most effective conversion ratio with the fewest adverse effects (AEs) when switching from pramipexole to ropinirole PR. Sixty patients with PD taking pramipexole were converted overnight to ropinirole PR at ratios of 1:3, 1:4, or 1:5 such that 20 consecutive subjects were enrolled in each group. Ropinirole PR dose adjustments were allowed to maintain efficacy or to reduce AEs. An overnight switch from pramipexole to ropinirole PR was found to be well tolerated and AEs were typical for a dopamine agonist. The most common AEs were worsening of PD symptoms, dizziness, somnolence, and nausea, the majority of which resolved after dose adjustments. Thirteen subjects discontinued ropinirole PR before 4 weeks. These subjects were taking a significantly greater dose of pramipexole, the majority greater than 4 mg/day, and tended to have longer disease durations. A conversion ratio of 1 mg of pramipexole to 4 mg of ropinirole PR resulted in the fewest discontinuations of ropinirole PR, the fewest dose adjustments and the largest percentage of subjects that preferred ropinirole PR. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22750
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001793
- to stream Istex, to step Curation: 001793
- to stream Istex, to step Checkpoint: 001055
- to stream PubMed, to step Corpus: 001B56
- to stream PubMed, to step Curation: 001B56
- to stream PubMed, to step Checkpoint: 001F56
- to stream Ncbi, to step Merge: 002824
- to stream Ncbi, to step Curation: 002824
- to stream Ncbi, to step Checkpoint: 002824
- to stream Main, to step Merge: 002D14
- to stream PascalFrancis, to step Corpus: 000D22
- to stream PascalFrancis, to step Curation: 001F97
- to stream PascalFrancis, to step Checkpoint: 000F85
- to stream Main, to step Merge: 003082
- to stream Main, to step Curation: 002453
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">An open‐label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease</title><author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name></author><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:93D489B2B706FAA32A128B4963FDC4FB08448F62</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22750</idno><idno type="url">https://api.istex.fr/document/93D489B2B706FAA32A128B4963FDC4FB08448F62/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001793</idno><idno type="wicri:Area/Istex/Curation">001793</idno><idno type="wicri:Area/Istex/Checkpoint">001055</idno><idno type="wicri:doubleKey">0885-3185:2009:Lyons K:an:open:label</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:19768728</idno><idno type="wicri:Area/PubMed/Corpus">001B56</idno><idno type="wicri:Area/PubMed/Curation">001B56</idno><idno type="wicri:Area/PubMed/Checkpoint">001F56</idno><idno type="wicri:Area/Ncbi/Merge">002824</idno><idno type="wicri:Area/Ncbi/Curation">002824</idno><idno type="wicri:Area/Ncbi/Checkpoint">002824</idno><idno type="wicri:Area/Main/Merge">002D14</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:09-0482407</idno><idno type="wicri:Area/PascalFrancis/Corpus">000D22</idno><idno type="wicri:Area/PascalFrancis/Curation">001F97</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000F85</idno><idno type="wicri:doubleKey">0885-3185:2009:Lyons K:an:open:label</idno><idno type="wicri:Area/Main/Merge">003082</idno><idno type="wicri:Area/Main/Curation">002453</idno><idno type="wicri:Area/Main/Exploration">002453</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">An open‐label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease</title><author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center, Kansas City, Kansas</wicri:regionArea><placeName><region type="state">Kansas</region></placeName></affiliation></author><author><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center, Kansas City, Kansas</wicri:regionArea><placeName><region type="state">Kansas</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-10-30">2009-10-30</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2121">2121</biblScope><biblScope unit="page" to="2127">2127</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">93D489B2B706FAA32A128B4963FDC4FB08448F62</idno><idno type="DOI">10.1002/mds.22750</idno><idno type="ArticleID">MDS22750</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Accidental Falls</term><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Benzothiazoles (administration & dosage)</term><term>Benzothiazoles (adverse effects)</term><term>Benzothiazoles (therapeutic use)</term><term>Cohort Studies</term><term>Dopamine Agonists (administration & dosage)</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (therapeutic use)</term><term>Dopamine agonist</term><term>Dose-Response Relationship, Drug</term><term>Drug conversion</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Female</term><term>Humans</term><term>Indoles (administration & dosage)</term><term>Indoles (adverse effects)</term><term>Indoles (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Patient Satisfaction</term><term>Pramipexole</term><term>Release</term><term>Ropinirole</term><term>dopamine agonist conversion</term><term>dopamine agonists</term><term>ropinirole prolonged release</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzothiazoles</term><term>Dopamine Agonists</term><term>Indoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzothiazoles</term><term>Dopamine Agonists</term><term>Indoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzothiazoles</term><term>Dopamine Agonists</term><term>Indoles</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Accidental Falls</term><term>Aged</term><term>Cohort Studies</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Patient Satisfaction</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Changement médicament</term><term>Libération</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Pramipexole</term><term>Ropinirole</term><term>Stimulant dopaminergique</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Ropinirole prolonged release (PR) is a once daily oral dopamine agonist approved for the treatment of Parkinson's disease (PD). The goal of this 4 week, open‐label study was to determine the most effective conversion ratio with the fewest adverse effects (AEs) when switching from pramipexole to ropinirole PR. Sixty patients with PD taking pramipexole were converted overnight to ropinirole PR at ratios of 1:3, 1:4, or 1:5 such that 20 consecutive subjects were enrolled in each group. Ropinirole PR dose adjustments were allowed to maintain efficacy or to reduce AEs. An overnight switch from pramipexole to ropinirole PR was found to be well tolerated and AEs were typical for a dopamine agonist. The most common AEs were worsening of PD symptoms, dizziness, somnolence, and nausea, the majority of which resolved after dose adjustments. Thirteen subjects discontinued ropinirole PR before 4 weeks. These subjects were taking a significantly greater dose of pramipexole, the majority greater than 4 mg/day, and tended to have longer disease durations. A conversion ratio of 1 mg of pramipexole to 4 mg of ropinirole PR resulted in the fewest discontinuations of ropinirole PR, the fewest dose adjustments and the largest percentage of subjects that preferred ropinirole PR. © 2009 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Kansas</li></region></list><tree><country name="États-Unis"><region name="Kansas"><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name></region><name sortKey="Pahwa, Rajesh" sort="Pahwa, Rajesh" uniqKey="Pahwa R" first="Rajesh" last="Pahwa">Rajesh Pahwa</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002453 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002453 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:93D489B2B706FAA32A128B4963FDC4FB08448F62
|texte= An open‐label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |